New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - leflunomide 100mg - film coated tablet - 100 mg - active: leflunomide 100mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 8000 magnesium stearate maize starch povidone purified talc titanium dioxide - arava is indicated for the treatment of: · rheumatoid arthritis, to improve signs and symptoms to retard joint destruction and to improve functional ability and quality of life. leflunomide may be used in patients who have failed to respond to other treatments or as a first line of treatment in patients who have a contraindication to other treatments. · active psoriatic arthritis. arava is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - promethazine teoclate 25mg - tablet - 25 mg - active: promethazine teoclate 25mg excipient: dextrin lactose monohydrate magnesium stearate purified talc starch - prevention and treatment of travel sickness.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - ciclopirox 8% - nail lacquer - 8 % - active: ciclopirox 8% excipient: butyl ester of pvm/ma copolymer ethyl acetate isopropyl alcohol nitrogen

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - ciclopirox olamine 1%{relative} - topical cream - 1% w/w - active: ciclopirox olamine 1%{relative}

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - ciclopirox olamine 1%{relative} - topical solution - 1% w/v - active: ciclopirox olamine 1%{relative}

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sodium valproate 199.8mg; valproic acid 87mg (as navalproate 100.3mg) - modified release tablet - 300 mg - active: sodium valproate 199.8mg valproic acid 87mg (as navalproate 100.3mg) excipient: erythrosine ethylcellulose hydrated silica hypromellose   indigo carmine iron oxide black propylene glycol purified water titanium dioxide - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - rasburicase 7.5mg - powder for infusion - 7.5 mg - active: rasburicase 7.5mg excipient: alanine dibasic sodium phosphate dihydrate dibasic sodium phosphate dodecahydrate mannitol monobasic sodium phosphate poloxamer 188 water for injection - the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus haemagglutinin 15ug (a h1n1 - strain to be confirmed prior to marketing); influenza virus type a haemagglutinin 15ug (h3n2 - strain to be confirmed prior to marketing); influenza virus type b haemagglutinin 15ug (strain to be confirmed prior to marketing) - suspension for injection - 15 mcg - active: influenza virus haemagglutinin 15ug (a h1n1 - strain to be confirmed prior to marketing) influenza virus type a haemagglutinin 15ug (h3n2 - strain to be confirmed prior to marketing) influenza virus type b haemagglutinin 15ug (strain to be confirmed prior to marketing) excipient: dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/california/7/2009 (h1n1) - like strain 9ug (a/california/7/2009 nymc x-179a); influenza virus a/texas/50/2012 (h3n2) like strain 9ug (a/texas/50/2012 nymc x-223a); influenza virus b/massachusetts/2/2012 like strain 9ug (wild type) - suspension for injection - 9 mcg - active: influenza virus a/california/7/2009 (h1n1) - like strain 9ug (a/california/7/2009 nymc x-179a) influenza virus a/texas/50/2012 (h3n2) like strain 9ug (a/texas/50/2012 nymc x-223a) influenza virus b/massachusetts/2/2012 like strain 9ug (wild type) excipient: dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide water for injection - intanza 9mcg is indicated for prophylaxis of influenza in adults from 18 to 59 years of age. the use of intanza 9mcg in new zealand should be based on the ministry of health recommendations for influenza vaccination as published in the current new zealand immunisation handbook.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - neisseria meningitidis group a polysaccharide 50ug; neisseria meningitidis group c polysaccharide 50ug; neisseria meningitidis group w135 polysaccharide 50ug; neisseria meningitidis group y polysaccharide 50ug - injection with diluent - 0.5 ml - active: neisseria meningitidis group a polysaccharide 50ug neisseria meningitidis group c polysaccharide 50ug neisseria meningitidis group w135 polysaccharide 50ug neisseria meningitidis group y polysaccharide 50ug excipient: lactose monohydrate sodium chloride purified water - menomune® acyw-135 is indicated for active immunisation of adults and children older than 2 years against disease caused by neisseria meningitidis groups a, c, y and w-135, the major manifestation being meningococcal meningitis. vaccination may be considered for the following individuals: · travellers to countries recognised as having highly endemic or epidemic disease. · control of epidemics of infection caused by neisseria meningitidis groups a, c, y and w-135 in confined communities. · individuals at particular high risk of acquiring meningococcal infection, including persons with anatomic or functional asplenia. · close contacts of persons with meningococcal disease due to groups a, c, y and w-135, as an adjunct to appropriate chemoprophylaxis.